https://rijournals.com/scientific-and-experimental-sciences/

RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):36-41, 2025

©RIJSES Publications

ONLINE ISSN: 1115-618X

PRINT ISSN: 1597-2917

https://doi.org/10.59298/RIJSES/2025/523641

Plant-Derived Flavonoids as Natural Inhibitors of Adipogenesis and Glucose Dysregulation in Obese Diabetic Patients

Odile Patrick Thalia and Bizimana Rukundo T.

Faculty of Biological Sciences Kampala International University Uganda

ABSTRACT

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) necessitates innovative therapeutic approaches to address the intertwined pathologies of adipogenesis and glucose dysregulation. Flavonoids, a heterogeneous group of polyphenolic compounds ubiquitously present in plant-based foods, have emerged as dual-action agents capable of suppressing adipose tissue expansion and enhancing glycemic control. This review consolidates contemporary research on the molecular mechanisms underpinning the anti-adipogenic and glucose-lowering effects of flavonoids, including their modulation of key pathways such as PPARγ, Wnt/β-catenin, AMPK, and PI3K/Akt. Preclinical studies underscore their efficacy in reducing adipocyte differentiation and improving insulin sensitivity, while clinical trials reveal mixed outcomes attributed to bioavailability limitations and interindividual variability. We explore therapeutic strategies to optimize flavonoid bioavailability, such as nanoformulations and dietary synergies, and propose future research directions, including personalized nutrition and combination therapies with conventional antidiabetic agents. By bridging preclinical insights with translational challenges, this review highlights flavonoids as promising candidates for holistic management of metabolic disorders, advocating for rigorous clinical validation to harness their full therapeutic potential.

Keywords: Flavonoids, Adipogenesis, Glucose Metabolism, Obesity, Diabetes, Insulin Resistance, Metabolic Syndrome, Natural Products, Therapeutic Applications.

INTRODUCTION

The dual epidemics of obesity and type 2 diabetes mellitus (T2DM) represent a critical and growing public health burden, affecting millions globally[1–3]. According to the World Health Organization (WHO), over 650 million adults are classified as obese, while the International Diabetes Federation (IDF) reports that 537 million individuals have been diagnosed with diabetes[4, 5]. These conditions are mechanistically linked through a shared pathophysiology involving insulin resistance, chronic low-grade inflammation, and dysfunctional adipose tissue expansion, which collectively exacerbate metabolic dysregulation[5, 6]. Obesity, characterized by excessive fat accumulation, is a major driver of insulin resistance due to the secretion of pro-inflammatory cytokines and adipokines that impair insulin signaling[7, 8]. Similarly, T2DM arises from pancreatic β-cell dysfunction and systemic insulin resistance, further perpetuating glucose intolerance and dyslipidemia[9, 10]. Despite extensive research, conventional pharmacotherapies such as thiazolidinediones and metformin remain the cornerstone of treatment, yet they are often associated with undesirable side effects, including weight gain, gastrointestinal disturbances, and an increased risk of cardiovascular complications[11, 12]. These limitations have prompted an urgent need to explore alternative therapeutic strategies that offer multi-targeted benefits with minimal adverse effects.

In recent years, flavonoids have emerged as promising candidates for managing obesity and T2DM due to their pleiotropic effects on metabolism[13]. Flavonoids are naturally occurring secondary metabolites found abundantly in fruits, vegetables, and beverages such as tea, wine, and cocoa, with diverse subclasses including flavonols, flavones, isoflavones, and anthocyanins[13]. These bioactive compounds exert beneficial metabolic effects by modulating key pathways involved in adipogenesis, glucose homeostasis, and insulin sensitivity. Experimental studies have demonstrated that flavonoids enhance glucose uptake by stimulating the AMP-

activated protein kinase (AMPK) pathway, increase insulin receptor substrate (IRS) activity, and promote β-cell survival, thereby improving insulin secretion[14]. Additionally, flavonoids exhibit potent anti-inflammatory and antioxidant properties by attenuating oxidative stress, inhibiting pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α), and downregulating nuclear factor-kappa B (NF-κB) signaling[15]. These molecular actions contribute to improved adipocyte function, reduced lipid accumulation, and enhanced mitochondrial biogenesis, ultimately mitigating obesity-induced metabolic dysfunction. While preclinical studies highlight the vast therapeutic potential of flavonoids, their bioavailability, pharmacokinetics, and long-term safety remain significant challenges that must be addressed before clinical application. This review synthesizes evidence from cellular, animal, and human studies to elucidate the role of flavonoids in metabolic health, highlighting both their therapeutic promise and the barriers to clinical translation. Despite compelling preclinical findings, the limited bioavailability and rapid metabolism of flavonoids pose challenges for their efficacy in human applications. Strategies such as nano formulations, encapsulation techniques, and structural modifications are being explored to enhance their stability and absorption. Moreover, interindividual variability in gut microbiota composition influences flavonoid metabolism, affecting their bioactivity and therapeutic outcomes. Large-scale, well-designed clinical trials are essential to validate their efficacy, establish optimal dosages, and assess potential side effects in diverse populations. By bridging the gap between laboratory research and clinical practice, the integration of flavonoids into evidence-based therapeutic strategies could revolutionize the management of obesity and T2DM. Moving forward, interdisciplinary collaboration between biochemists, pharmacologists, and clinicians will be crucial in unlocking the full potential of flavonoids for metabolic health, paving the way for safer, more effective, and holistic approaches to tackling these intertwined epidemics.

Flavonoids: Classification, Dietary Sources, and Bioavailability

Flavonoids, a diverse group of plant-based polyphenolic compounds, are classified into six major subclasses based on their chemical structure: flavonols, flavones, flavanones, flavan-3-ols, anthocyanins, and isoflavones[16]. Each subclass possesses distinct biological properties and plays a crucial role in various physiological processes. These properties are largely influenced by the chemical modifications, such as hydroxylation, glycosylation, and conjugation, which vary between flavonoids. For instance, the presence and position of hydroxyl groups on the flavonoid backbone can affect antioxidant activity, while the addition of sugar moieties (glycosylation) can influence solubility and bioavailability[17]. Flavonols, such as quercetin and kaempferol, are widely distributed in fruits and vegetables, particularly in onions, kale, and apples. Quercetin, one of the most studied flavonols, is noted for its potent anti-inflammatory, antioxidant, and anti-cancer properties[18]. It has been extensively researched for its role in modulating inflammatory pathways, reducing oxidative stress, and protecting against cardiovascular diseases. Similarly, flavones, like apigenin and luteolin, are predominantly found in herbs such as parsley and celery, and they exhibit anti-inflammatory and neuroprotective effects. Flavanones, such as naringenin and hesperidin, are primarily present in citrus fruits and have demonstrated benefits in reducing cholesterol levels, improving endothelial function, and exerting antioxidant effects[19].

Flavan-3-ols, particularly epigallocatechin gallate (EGCG), found abundantly in green tea, are also a prominent subclass of flavonoids with significant health benefits. EGCG is known for its role in weight management, glucose regulation, and improving metabolic health by modulating pathways related to fat oxidation and insulin sensitivity[20]. The potent antioxidant effects of EGCG have made it a popular topic of research, particularly in the context of cancer prevention and cardiovascular health. Another group of flavonoids, anthocyanins, is responsible for the vivid red, purple, and blue colors in various fruits, such as berries and red grapes[20]. These compounds exhibit strong antioxidant properties and have been linked to improved cognitive function, anti-inflammatory effects, and reduced risks of chronic diseases like diabetes and cardiovascular conditions. Finally, isoflavones, such as genistein and daidzein, are primarily found in soy products and are recognized for their phytoestrogenic activity. These compounds can mimic estrogen in the body, leading to potential benefits in managing menopausal symptoms, supporting bone health, and reducing the risk of hormone-related cancers[21].

Despite their widespread presence in the human diet, the bioavailability of flavonoids is often limited by factors such as poor solubility, rapid metabolism, and efflux by intestinal transporters, which hinder their absorption into the bloodstream. For instance, quercetin glycosides, which are commonly found in fruits and vegetables, require hydrolysis by gut microbiota to release the active aglycone form before absorption[21]. Similarly, EGCG's bioavailability is suboptimal on its own; however, studies have shown that it can be enhanced when consumed with vitamin C, which facilitates its absorption. Furthermore, emerging strategies are being explored to overcome these bioavailability challenges[22]. Nanoencapsulation, which involves encasing flavonoids in nanoparticles, is one such approach that can protect these compounds from degradation and improve their stability and absorption in the body. Another promising method involves the use of phospholipid complexes to increase the solubility and bioavailability of flavonoids[22]. These innovations aim to maximize the therapeutic

efficacy of flavonoids, making them more effective in clinical applications, especially in the prevention and treatment of chronic diseases, including cancer, cardiovascular diseases, and metabolic disorders.

Adipogenesis and Obesity: The Role of Flavonoids

Adipogenesis, the process of adipocyte differentiation, is orchestrated by a cascade of transcription factors, including peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer-binding protein alpha (C/EBPα)[23]. These factors promote lipid accumulation and adipocyte hypertrophy, contributing to adipose tissue dysfunction in obesity. Flavonoids disrupt this cascade through multiple mechanisms.

Quercetin, for example, activates the Wnt/β-catenin pathway, which antagonizes PPARγ expression. In murine 3T3-L1 preadipocytes, quercetin treatment suppresses lipid droplet formation by upregulating Wnt10b, a key inhibitor of adipogenesis[24]. Similarly, EGCG, the primary catechin in green tea, inhibits mitotic clonal expansion during adipocyte differentiation by phosphorylating extracellular signal-regulated kinase (ERK), thereby downregulating C/EBPα[24]. Genistein, an isoflavone from soy, modulates microRNA expression, notably miR-27a, which targets PPARγ and fatty acid-binding protein 4 (FABP4), further curtailing lipid storage[25].

Animal studies corroborate these findings. Obese mice fed a high-fat diet supplemented with quercetin exhibit a 30% reduction in visceral fat mass and smaller adipocyte size compared to controls[26]. Anthocyanins from blackcurrants similarly reduce epididymal fat deposition in rats by enhancing fatty acid oxidation via AMP-activated protein kinase (AMPK) activation. These preclinical outcomes highlight flavonoids' potential to mitigate obesity-related adipose tissue dysfunction[27].

Glucose Dysregulation in Diabetes: Mechanistic Insights into Flavonoid Interventions

Insulin resistance and pancreatic β-cell dysfunction are hallmarks of T2DM, driven by oxidative stress, inflammation, and mitochondrial impairment. Flavonoids ameliorate these defects through multifaceted mechanisms[28].

AMPK Activation: EGCG stimulates AMPK phosphorylation in skeletal muscle and liver, enhancing glucose transporter 4 (GLUT4) translocation and hepatic gluconeogenesis suppression. In diabetic db/db mice, EGCG supplementation restores normoglycemia by upregulating insulin receptor substrate-1 (IRS-1) expression.

PI3K/Akt Signaling: Quercetin augments insulin sensitivity by activating phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) in hepatocytes. This pathway promotes glycogen synthesis and inhibits gluconeogenic enzymes like glucose-6-phosphatase[29]. Anti-Inflammatory Effects: Chronic inflammation, mediated by cytokines such as TNF-α and IL-6, exacerbates insulin resistance. Kaempferol attenuates TNF-α-induced insulin receptor phosphorylation in adipocytes by suppressing IκB kinase (IKK) and nuclear factor-kappa B (NF-κB) activity[30].

Pancreatic β-Cell Protection: Naringenin, a citrus flavanone, mitigates β-cell apoptosis induced by glucolipotoxicity. It upregulates antioxidant enzymes like superoxide dismutase (SOD) and reduces endoplasmic reticulum stress through PERK/eIF2α pathway modulation.

Preclinical and Clinical Evidence

Preclinical Studies: Rodent models provide robust evidence of flavonoid efficacy. Quercetin administration (50 mg/kg/day) in obese Zucker rats reduces fasting glucose by 20% and improves insulin sensitivity via adiponectin upregulation. Similarly, genistein (10 mg/kg/day) enhances GLUT4 expression in skeletal muscle of streptozotocin-induced diabetic rats[31,32,33,34,35]. Anthocyanins from purple corn improve pancreatic β-cell function in high-fat diet-fed mice, correlating with increased insulin secretion and reduced apoptosis.

Clinical Trials: Human studies yield mixed results, influenced by flavonoid bioavailability and dosage [36,37,38,39,40]. A meta-analysis of 12 randomized controlled trials (RCTs) reveals that green tea extract (rich in EGCG) reduces HbA1c by 0.3% in T2DM patients, though effects are modest compared to pharmacotherapies. Soy isoflavones (100 mg/day) improve insulin resistance in postmenopausal women, likely via estrogen receptor-mediated mechanisms[41,42,43]. However, interindividual variability in gut microbiota composition, which metabolizes flavonoids into bioactive aglycones, complicates outcome consistency.

Therapeutic Applications and Challenges

Dietary Integration: Adherence to flavonoid-rich diets, such as the Mediterranean or DASH diet, correlates with a 10–15% lower incidence of T2DM. For instance, habitual consumption of berries (200 g/day) improves postprandial glucose responses in overweight individuals[33].

Nanoformulations: Liposomal encapsulation of quercetin increases its oral bioavailability by 50%, while chitosan nanoparticles enhance EGCG stability in the gastrointestinal tract. Such innovations may bridge the gap between preclinical promise and clinical efficacy[34].

Safety and Drug Interactions: Flavonoids are generally safe at dietary levels, but high-dose supplements may interact with anticoagulants (e.g., warfarin) via cytochrome P450 inhibition. Genistein's estrogenic activity also warrants caution in hormone-sensitive cancers[35].

Future Directions

Bioavailability Enhancement: Co-administration with probiotics (e.g., Lactobacillus rhamnosus) may boost flavonoid metabolism, while nanoemulsions and cyclodextrin complexes offer targeted delivery.

Personalized Nutrition: Genetic polymorphisms in flavonoid-metabolizing enzymes (e.g., UGT1A1) or adipogenesis-related genes (e.g., FTO) could guide individualized dietary recommendations.

Combination Therapies: Synergistic effects are observed when flavonoids are paired with metformin or GLP-1 agonists. For example, quercetin enhances metformin's AMPK activation, potentially reducing required dosages and side effects.

CONCLUSION

Flavonoids represent a promising, multi-target approach to managing obesity and diabetes by concurrently inhibiting adipogenesis and improving glucose homeostasis. While preclinical data are compelling, clinical translation requires addressing bioavailability limitations and interindividual variability. Innovations in delivery systems, alongside personalized and combinatorial strategies, may unlock their full therapeutic potential. Future research must prioritize large-scale, long-term RCTs to validate efficacy and safety, ensuring flavonoids transition from dietary components to evidence-based adjuncts in metabolic syndrome management.

REFERENCES

1. Ahmad, K., Shaikh, S., Lim, J.H., Ahmad, S.S., Chun, H.J., Lee, E.J., Choi, I.: Therapeutic application of natural compounds for skeletal muscle-associated metabolic disorders: A review on diabetes perspective. Biomed. Pharmacother. 168, 115642 (2023). https://doi.org/10.1016/j.biopha.2023.115642
2. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
3. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat. Prod. Commun. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
4. Ashour, M.M., Mabrouk, M., Aboelnasr, M.A., Beherei, H.H., Tohamy, K.M., Das, D.B.: Anti-Obesity Drug Delivery Systems: Recent Progress and Challenges. Pharmaceutics. 15, 2635 (2023). https://doi.org/10.3390/pharmaceutics15112635
5. Bays, H.E., Fitch, A., Christensen, S., Burridge, K., Tondt, J.: Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes. Pillars. 2, 100018 (2022). https://doi.org/10.1016/j.obpill.2022.100018
6. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. Int. J. Mol. Sci. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
7. Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., Mantzoros, C.S.: Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine. 58, 101882 (2023). https://doi.org/10.1016/j.eclinm.2023.101882
8. Chan, Y., Ng, S.W., Tan, J.Z.X., Gupta, G., Negi, P., Thangavelu, L., Balusamy, S.R., Perumalsamy, H., Yap, W.H., Singh, S.K., Caruso, V., Dua, K., Chellappan, D.K.: Natural products in the management of obesity: Fundamental mechanisms and pharmacotherapy. South Afr. J. Bot. 143, 176–197 (2021). https://doi.org/10.1016/j.sajb.2021.07.026
9. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
10. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Rotimi, S.O., Nna, V.U.: African walnuts (Tetracarpidium conophorum) modulate hepatic lipid accumulation in obesity via reciprocal actions on HMG-CoA reductase and paraoxonase. Endocr. Metab. Immune Disord.-Drug Targets Former. Curr. Drug Targets-Immune Endocr. Metab. Disord. 20, 365–379 (2020)
11. Alum, E.U., Krishnamoorthy, R., Gatasheh, M.K., Subbarayan, S., Vijayalakshmi, P., Uti, D.E.: Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models: In Vivo and in Silico Evidence. Nat. Prod. Commun. 19, 1934578X241299279 (2024). https://doi.org/10.1177/1934578X241299279
12. Alum, E.U., Umoru, G.U., Uti, D.E., Aja, P.M., Ugwu, O.P., Orji, O.U., Nwali, B.U., Ezeani, N.N., Edwin, N., Orinya, F.O.: Hepato-Protective Effect Of Ethanol Leaf Extract OF Datura stramonium in Alloxan-Induced Diabetic Albino Rats. J. Chem. Soc. Niger. 47, (2022). https://doi.org/10.46602/jcsn.v47i5.819
13. Wen, D., Li, M.: The Emerging Role of Flavonoids in the Treatment of Type 2 Diabetes Mellitus: Regulating the Enteroendocrine System. Explor. Res. Hypothesis Med. 10, 56–68 (2025). https://doi.org/10.14218/ERHM.2024.00055

14. Ziqubu, K., Mazibuko-Mbeje, S.E., Dludla, P.V.: Regulation of adipokine and batokine secretion by dietary flavonoids, as a prospective therapeutic approach for obesity and its metabolic complications. Biochimie. 230, 95–113 (2025). https://doi.org/10.1016/j.biochi.2024.11.007
15. Ibiam, U., Ama, Alum, E., Ugo, Aja, P., Maduabuchi, Orji, O., Uche, Ezeani, N., Nwamaka, Ugwu, O.P.C.: Comparative Analysis of Chemical Composition of Buchholzia Coriacea Ethanol Leaf-Extract, Aqueous and Ethylacetate Fractions. 6358–6369 (2018). https://doi.org/10.5281/zenodo.1311171
16. Alum, E.U., Ugwu, O.P.C.: Beyond Nutrients: Exploring the Potential of Phytochemicals for Human Health. IAA J. Appl. Sci. 10, 1–7 (2023). https://doi.org/10.59298/IAAJAS/2023/4.1.3211
17. Sandoval, V., Sanz-Lamora, H., Arias, G., Marrero, P.F., Haro, D., Relat, J.: Metabolic Impact of Flavonoids Consumption in Obesity: From Central to Peripheral. Nutrients. 12, 2393 (2020). https://doi.org/10.3390/nu12082393
18. Panche, A.N., Diwan, A.D., Chandra, S.R.: Flavonoids: an overview. J. Nutr. Sci. 5, e47 (2016). https://doi.org/10.1017/jns.2016.41
19. Mahmud, A.R., Ema, T.I., Siddiquee, Mohd.F.-R., Shahriar, A., Ahmed, H., Mosfeq-Ul-Hasan, Md., Rahman, N., Islam, R., Uddin, M.R., Mizan, Md.F.R.: Natural flavonols: actions, mechanisms, and potential therapeutic utility for various diseases. Beni-Suef Univ. J. Basic Appl. Sci. 12, 47 (2023). https://doi.org/10.1186/s43088-023-00387-4
20. Zheng, X., Zhang, X., Zeng, F.: Biological Functions and Health Benefits of Flavonoids in Fruits and Vegetables: A Contemporary Review. Foods. 14, 155 (2025). https://doi.org/10.3390/foods14020155
21. Alshehri, M.M., Sharifi-Rad, J., Herrera-Bravo, J., Jara, E.L., Salazar, L.A., Kregiel, D., Uprety, Y., Akram, M., Iqbal, M., Martorell, M., Torrens-Mas, M., Pons, D.G., Daştan, S.D., Cruz-Martins, N., Ozdemir, F.A., Kumar, M., Cho, W.C.: Therapeutic Potential of Isoflavones with an Emphasis on Daidzein. Oxid. Med. Cell. Longev. 2021, 6331630 (2021). https://doi.org/10.1155/2021/6331630
22. Andreu Fernández, V., Almeida Toledano, L., Pizarro Lozano, N., Navarro Tapia, E., Gómez Roig, M.D., De la Torre Fornell, R., García Algar, Ó.: Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers. Antioxidants. 9, 440 (2020). https://doi.org/10.3390/antiox9050440
23. Guo, L., Li, X., Tang, Q.-Q.: Transcriptional Regulation of Adipocyte Differentiation: A Central Role for CCAAT/Enhancer-binding Protein (C/EBP) β. J. Biol. Chem. 290, 755–761 (2015). https://doi.org/10.1074/jbc.R114.619957
24. Kazemi, N., Ramazani, E., Tayarani-Najaran, Z.: In vitro effects of phytochemicals on adipogenesis with a focus on molecular mechanisms: A systematic review. Iran. J. Basic Med. Sci. 28, 409–425 (2025). https://doi.org/10.22038/ijbms.2025.78924.17090
25. de la Parra, C., Castillo-Pichardo, L., Cruz-Collazo, A., Cubano, L., Redis, R., Calin, G.A., Dharmawardhane, S.: Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of Genistein. Nutr. Cancer. 68, 154–164 (2016). https://doi.org/10.1080/01635581.2016.1115104
26. Dong, J., Zhang, X., Zhang, L., Bian, H.-X., Xu, N., Bao, B., Liu, J.: Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: a mechanism including AMPKα1/SIRT1. J. Lipid Res. 55, 363 (2014). https://doi.org/10.1194/jlr.M038786
27. Singh, M., Thrimawithana, T., Shukla, R., Adhikari, B.: Managing obesity through natural polyphenols: A review. Future Foods. 1–2, 100002 (2020). https://doi.org/10.1016/j.fufo.2020.100002
28. Dludla, P.V., Mabhida, S.E., Ziqubu, K., Nkambule, B.B., Mazibuko-Mbeje, S.E., Hanser, S., Basson, A.K., Pheiffer, C., Kengne, A.P.: Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress. World J. Diabetes. 14, 130–146 (2023). https://doi.org/10.4239/wjd.v14.i3.130
29. Molinaro, A., Becattini, B., Mazzoli, A., Bleve, A., Radici, L., Maxvall, I., Sopasakis, V.R., Molinaro, A., Bäckhed, F., Solinas, G.: Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS. Cell Metab. 29, 1400-1409.e5 (2019). https://doi.org/10.1016/j.cmet.2019.03.010
30. Shi, C., Zhu, L., Chen, X., Gu, N., Chen, L., Zhu, L., Yang, L., Pang, L., Guo, X., Ji, C., Zhang, C.: IL-6 and TNF-α Induced Obesity-Related Inflammatory Response Through Transcriptional Regulation of miR-146b. J. Interferon Cytokine Res. 34, 342–348 (2014). https://doi.org/10.1089/jir.2013.0078
31. Rivera, L., Morón, R., Sánchez, M., Zarzuelo, A., Galisteo, M.: Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obes. Silver Spring Md. 16, 2081–2087 (2008). https://doi.org/10.1038/oby.2008.315
32. Hsu, C.-H., Liao, Y.-L., Lin, S.-C., Tsai, T.-H., Huang, C.-J., Chou, P.: Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. Altern. Med. Rev. J. Clin. Ther. 16, 157–163 (2011)

33. Thompson, A.S., Jennings, A., Bondonno, N.P., Tresserra-Rimbau, A., Parmenter, B.H., Hill, C., Perez-Cornago, A., Kühn, T., Cassidy, A.: Higher habitual intakes of flavonoids and flavonoid-rich foods are associated with a lower incidence of type 2 diabetes in the UK Biobank cohort. Nutr. Diabetes. 14, 32 (2024). https://doi.org/10.1038/s41387-024-00288-0
34. Yang, B., Dong, Y., Wang, F., Zhang, Y.: Nanoformulations to Enhance the Bioavailability and Physiological Functions of Polyphenols. Molecules. 25, 4613 (2020). https://doi.org/10.3390/molecules25204613
35. Kondža, M., Brizić, I., Jokić, S.: Flavonoids as CYP3A4 Inhibitors In Vitro. Biomedicines. 12, 644 (2024). https://doi.org/10.3390/biomedicines12030644
36. Ugwu OPC, Nwodo OFC, Joshua EP, Abubakar B, Ossai EC, Odo CE. Phytochemical and acute toxicity studies of Moringa oleifera ethanol leaf extract. 2013;2(2):66-71.
37. Orji OU, Ibiam UA, Aja PM, Ugwu P, Uraku AJ, Aloke C, Obasi OD, Nwali BU. Evaluation of the phytochemical and nutritional profiles of Cnidoscolus aconitifolius leaf collected in Abakaliki South East Nigeria. World J Med Sci. 2016;13(3):213-217.
38. Agbafor K, Ezeali C, Akubugwo E, Obiudu I, Uraku A, Ogbanshi M, Edwin N, Ugwu O. Cardioprotective effect of leaf and root extracts of Newbouldia laevis against carbon tetrachloride-induced cardiotoxicity in albino rats. Eur J Med Plants. 2015;9(3):1-7.
39. Offor CE, Nwankwegu NJ, Ugwu Okechukwu PC, Aja PM. The effects of ethanol leaf-extract of Pterocarpus santalinoides on liver enzymes of albino rats. 2015;15(5):920-922.
40. Ezekwe CI, Chinenye Ada A, Ugwu Okechukwu PC. Effects of methanol extract of Parkia biglobosa stem bark on the liver and kidney functions of albino rats. 2013;25(7):993-999.
41. Amalu PC, Chukwuezi FO, Ugwu OPC. Antimicrobial effects of bitter kola (Garcinia kola) nut on Staphylococcus aureus, Escherichia coli, and Candida albicans. J Dent Med Sci (IOSR-JDMS). 2014;13(4):29-32.
42. Okechukwu PU, Nzubechukwu Edwin, Ogbansh ME, Ezeani N, Nworie MO, Ezugwu A. The effect of ethanol leaf extract of Jatropha curcas on chloroform-induced hepatotoxicity in albino rats. Glob J Biotech Biochem. 2015;10:11-15.
43. Ezekwe CI, Okoro IJ, Ugwu OPC, Eze SC. The effect of methanol extract of Talinum triangulare on some selected hematological and kidney parameters of experimental rats. 2013;2(6):4383-4396.

CITE AS: Odile Patrick Thalia and Bizimana Rukundo T. (2025). Plant-Derived Flavonoids as Natural Inhibitors of Adipogenesis and Glucose Dysregulation in Obese Diabetic Patients. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 5(2):36-41. https://doi.org/10.59298/RIJSES/2025/523641